What Is Myeloma

Senesco Technologies higher after FDA removes hold on new drug application

While there are many types of cancer, the ways that we can fight the disease are few, and these treatments seem little different than the barbaric bloodletting or bleeding of a patient that was often recommended by physicians before modern medicine. Radiation and chemotherapy, which are the current standard of care for cancer, essentially kill cells until the cancer can no longer be found in the body, with the hope that the body can withstand the treatment. New treatments for cancer are desperately needed, and one that may use the body’s natural processes through gene therapy may provide a window of opportunity for new treatment. Certain aspects of gene therapy have been found to regulate cell death, and have been used to great effect for what seems like a simpler use, prolonging the shelf life of bananas. Apoptosis, or programmed cell death, is the vehicle that Senesco Technologies believes could be used to treat major medical conditions such as diabetes, cardiovascular disease and cancer.  Senesco Technologies ( Amex:SNT ) has recently been granted Orphan Drug Status and submitted their first Investigational New Drug application (IND) with the FDA for their lead product candidate SNS01-T. SNS01-T has been developed for the treatment of multiple myeloma, an incurable blood cancer that causes an accumulation of cancerous plasma cells (a type of B cell normally responsible for antibody production) in the bone marrow, which leads to destruction of the bone and interference with the normal production of immune system cells. The American Cancer Society estimated that in 2010 there will be approximately 20,180 new cases of multiple myeloma diagnosed and 10,650 multiple myeloma-related deaths in the United States. Senesco’s SNS01-T technology is based on the discovery that the eIF5A gene has the ability to regulate apoptosis - as well as certain execution genes, pro-inflammatory cytokines (regulatory proteins), receptors and transcription factors - resulting in the ability to play a major role in the management of cell death and survival.  eIF5A modulates apoptosis by controlling the signaling pathways responsible for triggering cell death.  By acting as an arbitrageur between multiple pathways, the maximum benefit can be obtained, unlike competing technologies that act further "downstream" on individual targets.

Multiple Myeloma, what is the survival rate for this cancer ...

Free of charge for more than 1 yr with out a flare up, I would say the odds are very good he could make it to 5 decades. The oncologist will then treat it as a chronic, instead than acute situation, and your father will have to be monitored regularly for the relaxation of his existence. Flare ups will be treated with steroids and chemotherapy.

Numerous Myeloma is a extremely tricky disease. It is driven by a person’s metabolism, which is why youthful clients succumb the fastest.

100 Questions and Answers about Myeloma

PACES for the MRCP, 250 clinical cases

Medifocus Guidebook On: Multiple Myeloma

Still Here Kickin', A Story about Surviving Cancer

Multiple Myeloma